Featured Research

from universities, journals, and other organizations

Molecular imaging detects recurrent prostate cancer

Date:
June 7, 2010
Source:
Society of Nuclear Medicine
Summary:
Findings of a clinical trial indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

Findings of a clinical trial reported at the Society of Nuclear Medicine's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

"Despite definitive treatment, about 30 percent of prostate cancers recur," said David Schuster, M.D., director of the division of nuclear medicine and molecular imaging and assistant professor of radiology at Emory University School of Medicine, Atlanta, Ga. "This troubling statistic led our research team to diligently work on developing new techniques to more effectively detect and diagnose recurrent prostate tumors and associated cancers that have spread to nearby tissues and organs."

According to the authors, a radiotracer known as anti-18F-FACBC could be used to effectively and non-invasively detect and differentiate tumors recurring in the prostate and metastatic cancers that develop, most notably in the surrounding lymph nodes. "This may lead to custom-tailored treatments for prostate cancer patients that cater to their specific tumor type and progression of disease," added Schuster.

The new imaging agent, developed by Dr. Mark Goodman at Emory University, consists of a fluorine-based radioisotope paired with a synthetic amino-acid analog similar to the naturally-occurring amino acid L-leucine. Amino acids are essentially the building blocks of protein, and many cells have a system that controls the transport of amino acids into the cell in order to facilitate the production of new proteins. Upon injection, anti-18F-FACBC is absorbed by various cells by this transport system, but the "uptake," or admission of the agent, is much higher in aggressively multiplying cancer cells, which need more of these proteins in order to proliferate.

Researchers scanned 83 patients suspected of having recurrent prostate cancer using a hybrid positron emission tomography and computed tomography (PET/CT) system, a molecular imaging technique that displays both anatomical information and physiological processes in the body. Resulting scans were evaluated to determine the presence of recurrent prostate tumors and outlying tumors that had metastasized, or spread, to other tissues, including those of nearby bones and lymph nodes that tend be to a target for cancer metastases. The agent was able to positively identify recurrent carcinomas in the prostate region with 74-percent accuracy, and metastatic cancers with 96-percent accuracy, catching even small tumors within lymph nodes that other imaging agents could not detect. The ability to differentiate tumors recurring in the prostate from metastatic cancers with high accuracy is the most promising aspect of this PET radiotracer.

According to the American Cancer Society, prostate cancer is the leading cancer diagnosis in men besides skin cancer. More than 192,000 men in America were estimated to be diagnosed with prostate cancer in 2009, and 27,360 deaths were projected as a result of the disease.

Scientific Paper 456: D.M. Schuster, B. Savir-Baruch, R.K. Halkar, W. Yu, M.M. Goodman, Radiology, Emory University, Atlanta, Ga.; P.T. Nieh , V. Master, Urology, Emory University, Atlanta, Ga.; M.M. Lewis, Pathology and Laboratory Medicine, Emory University, Atlanta, Ga.; P.J. Rossi, Radiation Oncology, Emory University, Atlanta, Ga.; F.D. Bowman, Biostatistics and Bioinformatics, Emory University, Atlanta, Ga.; "Report of a clinical trial of anti-1 amino 3 [18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) PET-CT in recurrent prostate carcinoma," SNM's 57th Annual Meeting, June 5-9, 2010, Salt Lake City, Utah.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society of Nuclear Medicine. "Molecular imaging detects recurrent prostate cancer." ScienceDaily. ScienceDaily, 7 June 2010. <www.sciencedaily.com/releases/2010/06/100607065708.htm>.
Society of Nuclear Medicine. (2010, June 7). Molecular imaging detects recurrent prostate cancer. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2010/06/100607065708.htm
Society of Nuclear Medicine. "Molecular imaging detects recurrent prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2010/06/100607065708.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins